OTCMKTS:OTLC Oncotelic Therapeutics Q4 2025 Earnings Report $0.04 0.00 (-1.71%) As of 03:03 PM Eastern ProfileEarnings History Oncotelic Therapeutics EPS ResultsActual EPS$0.59Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncotelic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncotelic Therapeutics Announcement DetailsQuarterQ4 2025Date4/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oncotelic Therapeutics Earnings HeadlinesOTLC Share News TodayJuly 14, 2026 | uk.investing.comOncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion UnderwayJuly 7, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 20 at 1:00 AM | Profits Run (Ad)Oncotelic Therapeutics Enters New Convertible Note FinancingJune 29, 2026 | tipranks.comOncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003June 29, 2026 | globenewswire.comOncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026June 18, 2026 | globenewswire.comSee More Oncotelic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncotelic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncotelic Therapeutics and other key companies, straight to your email. Email Address About Oncotelic TherapeuticsOncotelic Therapeutics (OTCMKTS:OTLC) is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity. Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs. The company has conducted early‐phase clinical studies in solid tumors and is exploring combination strategies with immune checkpoint inhibitors. Oncotelic’s research and development efforts are focused on expanding the potential of its oncolytic platform across multiple cancer indications and optimizing its diagnostic capabilities to support personalized treatment strategies. Headquartered in Gaithersburg, Maryland, Oncotelic operates with a lean scientific and management team. Leadership is spearheaded by President and Chief Executive Officer Bryan M. Saltjian, Ph.D., who brings extensive experience in viral immunotherapy and biotechnology commercialization. Under his guidance, Oncotelic aims to advance its pipeline through clinical milestones and strategic partnerships that can bring its oncolytic and diagnostic innovations to the broader oncology community.View Oncotelic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
